June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit Model
Author Affiliations & Notes
  • Yonca Akova
    Ophthalmology, Bayindir Kavaklidere Hospital, Ankara, Turkey
    Ophthalmology, Baskent University Faculty of Medicine, Ankara, Turkey
  • Leyla Asena
    Ophthalmology, Baskent University Faculty of Medicine, Ankara, Turkey
  • Mustafa Göktas
    Pharmacology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Atilla Bozkurt
    Pharmacology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Umit Yasar
    Pharmacology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Gulten Karabay
    Histology, Baskent University Faculty of Medicine, Ankara, Turkey
  • Ebru Demiralay
    Pathology, Baskent University Faculty of Medicine, Ankara, Turkey
  • Footnotes
    Commercial Relationships Yonca Akova, None; Leyla Asena, None; Mustafa Göktas, None; Atilla Bozkurt, None; Umit Yasar, None; Gulten Karabay, None; Ebru Demiralay, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4291. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yonca Akova, Leyla Asena, Mustafa Göktas, Atilla Bozkurt, Umit Yasar, Gulten Karabay, Ebru Demiralay; Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4291. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: This study was carried out to determine the ocular pharmacokinetics, efficacy and potential endothelial toxicity of moxifloxacin (MF) after a single intracameral bolus injection of 500µg/0.1ml in a rabbit model.

Methods: Forty-eight eyes of 24 New Zealand White Rabbits were separated into 6 groups, each including 4 rabbits. 0.1 ml of 0.5% intracameral moxifloxacin (500µg) injection was performed to the right eyes and 0.1 ml of balanced salt solution to the left eyes (control). Aqueous humor (AH) and vitreous samples were collected at the 0.5th, 1st, 3rd, 6th, 12th and 24th hours from boths eyes of group 1, 2, 3, 4, 5 and 6 respectively. MF concentrations were determined by High Performance Liquid Chromatography. These were compared with the minimum inhibitory concentrations (MIC) and mutant prevention concentrations (MPC) for frequent endophthalmitis pathogens. Electron and light microscopical evaluation of the corneas were performed.

Results: Moxifloxacin reaches higher concentrations than the MIC of all common endophthalmitis pathogens in the aqueous humor and exceeds the mutant prevention concentration levels for Streptococcus pneumonia, Streptococcus viridans, flouroquinolone susceptible Coagulase-negative staphylococcus and flouroquinolone susceptible Staphylococcus aureus for 6 hours. The half-life of moxifloxacin in the AH was 2.2 hours. Electron and light microscopic evaluation revealed no noticeable sign of toxicity.

Conclusions: Peroperative intracameral moxifloxacin injection for endophthalmitis prophylaxis is a safe and effective method in uncomplicated phacoemulsification surgery.

Keywords: 422 antibiotics/antifungals/antiparasitics • 427 aqueous • 513 endophthalmitis  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×